CoChat

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

Open access
Judd, Julia, Abdel Karim, Nagla, Khan, Hina, Naqash, Abdul Rafeh, Baca, Yasmine, Xiu, Joanne, VanderWalde, Ari M., Mamdani, Hirva, Raez, Luis E., Nagasaka, Misako, Pai, Sachin Gopalkrishna, Socinski, Mark A., Nieva, Jorge J., Kim, Chul, Wozniak, Antoinette J., Ikpeazu, Chukwuemeka, de Lima Lopes, Gilberto, Spira, Alexander I., Korn, W. Michael, Kim, Edward S., Liu, Stephen V., Borghaei, Hossein · 2021 · Molecular Cancer Therapeutics
Cited by 194

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, KRAS-mutated non–small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development. Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of KRAS mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were analyzed by KRAS mutation type. Across the cohort, 4,706 (27.5%) samples harbored a KRAS mutation. The most common subtype was G12C (40%), followed by G12V (19%) and G12D (15%). The prevalence of KRAS mutations was 37.2% among adenocarcinomas and 4.4% in squamous cell carcinomas. Rates of high TMB (≥10 mutations/Mb) and PD-L1 expression varied across KRAS mutation subtypes. KRAS G12C was the most likely to be PD-L1 positive (65.5% TPS ≥ 1%) and PD-L1 high (41.3% TPS ≥ 50%). STK11 was mutated in 8.6% of KRAS wild-type NSCLC but more frequent in KRAS-mutant NSCLC, with the highest rate in G13 (36.2%). TP53 mutations were more frequent in KRAS wild-type NSCLC (73.6%). KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-21-0201

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 194

Metadata

Authors
Judd, J., Abdel Karim, N., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., Pai, S. G., Socinski, M. A., Nieva, J. J., Kim, C., Wozniak, A. J., Ikpeazu, C., de Lima Lopes, G., Spira, A. I., Korn, W. M., Kim, E. S., Liu, S. V., & Borghaei, H.
Venue
Molecular Cancer Therapeutics
Published
2021-12-01
Volume
20
Issue
12
Pages
2577-2584
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W3201087911
Cited by
194
References
27
FWCI
15.46
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-21-0201
The paper
Judd, J., Abdel Karim, N., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., Pai, S. G., Socinski, M. A., Nieva, J. J., Kim, C., Wozniak, A. J., Ikpeazu, C., de Lima Lopes, G., Spira, A. I., Korn, W. M., . . . Borghaei, H. (2021). Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-21-0201

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.